La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Repare Therapeutics Gestion
Gestion contrôle des critères 2/4
Le PDG Repare Therapeutics' est Lloyd Segal, nommé en Sep2016, a un mandat de 7.92 ans. La rémunération annuelle totale est $ 4.99M, composée du salaire de 12.3% et des bonus 87.7%, y compris les actions et options de la société. détient directement 0.28% des actions de la société, d'une valeur de $ 345.35K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.3 ans et 4.8 ans.
Informations clés
Lloyd Segal
Directeur général
US$5.0m
Rémunération totale
| Pourcentage du salaire du PDG | 12.3% |
| Durée du mandat du directeur général | 7.9yrs |
| Propriété du PDG | 0.3% |
| Durée moyenne d'occupation des postes de direction | 5.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.8yrs |
Mises à jour récentes de la gestion
Recent updates
Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Nov 19Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$5m | US$615k | -US$94m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$4m | US$592k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$132m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$4m | US$572k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$94m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$5m | US$505k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$430k | -US$27m |
Rémunération vs marché: La rémunération totale de Lloyd ($USD 4.99M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).
Rémunération et revenus: La rémunération de Lloyd a augmenté alors que l'entreprise n'est pas rentable.
PDG
Lloyd Segal (60 yo)
7.9yrs
Titularisation
US$4,991,804
Compensation
Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 7.9yrs | US$4.99m | 0.28% $ 365.4k | |
| Executive VP & CFO | 4.8yrs | US$1.93m | 0.034% $ 44.7k | |
| Executive VP & Chief Medical Officer | 5.3yrs | US$2.09m | 0.47% $ 619.3k | |
| Co-Founder | no data | pas de données | pas de données | |
| Co-Founder | no data | pas de données | pas de données | |
| Co-Founder | no data | pas de données | pas de données | |
| Executive VP & Chief Scientific Officer | 5.3yrs | US$1.83m | 0.098% $ 128.8k | |
| Executive Vice President of Human Resource | 1.3yrs | pas de données | 0.0037% $ 4.8k | |
| Executive Vice President of Discovery | 8.2yrs | pas de données | 0.055% $ 72.6k | |
| Executive VP | 2.6yrs | pas de données | 0.0092% $ 12.2k |
5.3yrs
Durée moyenne de l'emploi
53yo
Âge moyen
Gestion expérimentée: L'équipe de direction de RPTX est chevronnée et expérimentée (ancienneté moyenne 5.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 7.9yrs | US$4.99m | 0.28% $ 365.4k | |
| Independent Director | 4.2yrs | US$274.74k | 0.0094% $ 12.4k | |
| Independent Director | 4.9yrs | US$265.41k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$664.86k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$268.78k | 0% $ 0 | |
| Independent Director | less than a year | pas de données | pas de données | |
| Independent Director | 4.8yrs | US$265.31k | 0% $ 0 | |
| Independent Chairman | 2.9yrs | US$291.49k | 0.018% $ 23.3k | |
| Independent Director | 5.4yrs | US$272.99k | 0.019% $ 24.8k |
4.8yrs
Durée moyenne de l'emploi
59yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de RPTX sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).